Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction

No abstract is available for this paper.

• Publication year

  2018

• Venue

  American Journal of Hypertension

• Publication date

  2018-03-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/ajh/hpx210PMID 29228101PMCID PMC5861580
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Spironolactone Metabolites in TOPCAT - New Insights into Regional Variation.

  2017cited by this paper
• Use of Aldosterone Antagonists for Treatment of Uncontrolled Resistant Hypertension

  2017cited by this paper
• 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

  2016cited by this paper
• Regional differences in heart failure with preserved ejection fraction trials: when nephrology meets cardiology but east does not meet west.

  2015cited by this paper
• Resistant hypertension: what the cardiologist needs to know.

  2015influential reference
• Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

  2015cited by this paper
• The double challenge of resistant hypertension and chronic kidney disease.

  2015cited by this paper
• Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

  2015cited by this paper
• Geographic differences in heart failure trials

  2015cited by this paper
• Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial

  2015cited by this paper
• Spironolactone for heart failure with preserved ejection fraction.

  2014cited by this paper
• Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research

  2009cited by this paper
• Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

  2008cited by this paper
• Efficacy of low-dose spironolactone in subjects with resistant hypertension.

  2003cited by this paper

• Finerenone-Related Risk of Hypotension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.

  2025cites this paper
• Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease

  2025cites this paper
• ANMCO position paper: diagnosis and treatment of heart failure with preserved systolic function

  2025cites this paper
• Central Adiposity or Hypertension

  2025cites this paper
• Mineralocorticoid Receptor Antagonists in Heart Failure: An Update

  2024cites this paper
• Self-Reported Sodium Intake and Sodium Vulnerability in Heart Failure With Preserved Ejection Fraction.

  2024cites this paper
• Approaches in Managing Resistant Hypertension: A Review

  2024cites this paper
• A systematic review and meta-analysis of all sham and placebo controlled trials for resistant hypertension.

  2023cites this paper
• Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial

  2023cites this paper
• Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction

  2023cites this paper
• Experience of sacubitril/valsartan therapy in hypertension

  2023cites this paper
• Modulation of Pulsatile Left Ventricular Afterload by Renal Denervation in Heart Failure With Preserved Ejection Fraction

  2023cites this paper
• Denervation or stimulation? Role of sympatho-vagal imbalance in HFpEF with hypertension

  2023cites this paper
• Apparent Treatment-Resistant Hypertension Across the Spectrum of Heart Failure Phenotypes in the Swedish HF Registry.

  2022cites this paper
• Spironolactone affects cardiovascular and craniofacial development in zebrafish embryos (Danio rerio).

  2022cites this paper
• Comparative Safety and Effectiveness of Aldosterone Antagonists Versus Beta-Blockers as Fourth Agents in Patients With Apparent Resistant Hypertension

  2022cites this paper
• Cardiovascular Prognosis in Drug-Resistant Hypertension Stratified by 24-Hour Ambulatory Blood Pressure: The JAMP Study

  2021cites this paper
• Management of hypertension in heart failure with preserved ejection fraction: is there a blood pressure goal?

  2021cites this paper
• Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial.

  2021cites this paper
• Medical management of resistant hypertension: the role of sodium-glucose cotransporter 2 inhibitors (SGLT2i)

  2021cites this paper
• Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension

  2021cites this paper
• Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction

  2021cites this paper
• Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction

  2020cites this paper
• A study on early clinical screening and intervention scheme for primary hyperaldosteronism

  2020cites this paper
• Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension

  2020cites this paper
• A systematic review and meta-analysis

  2020influential citation
• Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre‐specified subgroup with heart failure

  2020cites this paper
• Hypertension and heart failure: focus on high-risk populations.

  2020cites this paper
• Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial

  2020cites this paper
• The Endothelial Mineralocorticoid Receptor: Contributions to Sex Differences in Cardiovascular Disease.

  2019cites this paper
• Resistant Hypertension: Diagnosis and Management.

  2019cites this paper
• Mineralocorticoid Receptor Antagonists Treatment in Resistant Hypertension and HFpEF: Evidence and Courage.

  2018cites this paper
• Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study

  2018cites this paper
• Is there a blood pressure lowering effect of MRAs in heart failure? An overview and meta-analysis

  2018cites this paper